Compare Heron Therapeutics Inc (HRTX) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Norwegian Cruise Line Holdings Ltd trades at $15.54 (market cap $7.11B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 104.5× Heron Therapeutics Inc's market cap, and Norwegian Cruise Line Holdings Ltd is more actively traded (22,683,268 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Norwegian Cruise Line Holdings Ltd for 68 Days on average.
| HRTX | NCLH | |
|---|---|---|
Market Cap | $68.01M | $7.11B |
Volume | 1,891,941 | 22,683,268 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $25.02 |
52-Week Low | $0.27 | $14.12 |
Typical Hold Time | 35 Days | 68 Days |
Enterprise Value | $174.75M | $21.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
NCLH trades at $15.495, up 2.96% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.48, exceeding expectations, and anticipates Q3 2026 results above guidance. Valuation metrics appear attractive with a P/E of 9.39 and P/S of 0.75. Analyst consensus is a Buy with a $20.86 price target, indicating 34% upside potential. Recent news highlights strategic initiatives like earlier booking resets and new senior note offerings to manage debt.
The outlook for NCLH is positive, driven by earnings momentum and favorable analyst sentiment, but risks include persistent yield pressure and high debt levels. Investment opportunity lies in the stock's discounted valuation relative to growth prospects, though investors must monitor Caribbean pricing trends and the company's ability to sustain profitability amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
